BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3569 related articles for article (PubMed ID: 26115367)

  • 21. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the validity of magnetic resonance imaging and positron emission tomography/computed tomography in the preoperative evaluation of patients with uterine corpus cancer.
    Park JY; Kim EN; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT; Nam JH
    Gynecol Oncol; 2008 Mar; 108(3):486-92. PubMed ID: 18201753
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of hybrid FDG PET/MRI compared with PET/CT in colorectal cancer staging and restaging: a pilot study.
    Paspulati RM; Partovi S; Herrmann KA; Krishnamurthi S; Delaney CP; Nguyen NC
    Abdom Imaging; 2015 Aug; 40(6):1415-25. PubMed ID: 26112492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-small cell lung cancer staging: efficacy comparison of integrated PET/CT versus 3.0-T whole-body MR imaging.
    Yi CA; Shin KM; Lee KS; Kim BT; Kim H; Kwon OJ; Choi JY; Chung MJ
    Radiology; 2008 Aug; 248(2):632-42. PubMed ID: 18552311
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 2-fluoro-2-deoxy-D-glucose positron emission tomography versus conventional imaging for the diagnosis of breast cancer and lymph node metastases.
    Shao M; Zi J; Wen G
    J Cancer Res Ther; 2018 Sep; 14(Supplement):S661-S666. PubMed ID: 30249884
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of neuroendocrine liver metastases: a comparison of dynamic contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography.
    Armbruster M; Sourbron S; Haug A; Zech CJ; Ingrisch M; Auernhammer CJ; Nikolaou K; Paprottka PM; Rist C; Reiser MF; Sommer WH
    Invest Radiol; 2014 Jan; 49(1):7-14. PubMed ID: 24002080
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PET/MR imaging in the detection and characterization of pulmonary lesions: technical and diagnostic evaluation in comparison to PET/CT.
    Rauscher I; Eiber M; Fürst S; Souvatzoglou M; Nekolla SG; Ziegler SI; Rummeny EJ; Schwaiger M; Beer AJ
    J Nucl Med; 2014 May; 55(5):724-9. PubMed ID: 24652827
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prone Versus Supine Breast FDG-PET/CT for Assessing Locoregional Disease Distribution in Locally Advanced Breast Cancer.
    Abramson RG; Lambert KF; Jones-Jackson LB; Arlinghaus LR; Williams J; Abramson VG; Chakravarthy AB; Yankeelov TE
    Acad Radiol; 2015 Jul; 22(7):853-9. PubMed ID: 25865435
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pulmonary lesion assessment: comparison of whole-body hybrid MR/PET and PET/CT imaging--pilot study.
    Schwenzer NF; Schraml C; Müller M; Brendle C; Sauter A; Spengler W; Pfannenberg AC; Claussen CD; Schmidt H
    Radiology; 2012 Aug; 264(2):551-8. PubMed ID: 22653189
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The added value of PET/Ce-CT/DW-MRI fusion in assessment of hepatic focal lesions: PET/Ce-CT/DW-MRI fusion in hepatic focal lesion.
    Salem S; Houseni M; Zidan L; Kandil A
    Nucl Med Biol; 2015 Jul; 42(7):637-42. PubMed ID: 25907467
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of PET and MR datasets in integrated 18F-FDG PET/MRI: A comparison of different MR sequences for whole-body restaging of breast cancer patients.
    Grueneisen J; Sawicki LM; Wetter A; Kirchner J; Kinner S; Aktas B; Forsting M; Ruhlmann V; Umutlu L
    Eur J Radiol; 2017 Apr; 89():14-19. PubMed ID: 28267530
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preoperative lymph-node staging of invasive urothelial bladder cancer with 18F-fluorodeoxyglucose positron emission tomography/computed axial tomography and magnetic resonance imaging: correlation with histopathology.
    Jensen TK; Holt P; Gerke O; Riehmann M; Svolgaard B; Marcussen N; Bouchelouche K
    Scand J Urol Nephrol; 2011 Mar; 45(2):122-8. PubMed ID: 21231796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic accuracy of dual-time-point 18F-FDG PET/CT for the detection of axillary lymph node metastases in breast cancer patients.
    Hahn S; Hecktor J; Grabellus F; Hartung V; Pöppel T; Kimmig R; Forsting M; Antoch G; Heusner TA
    Acta Radiol; 2012 Jun; 53(5):518-23. PubMed ID: 22547387
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Simultaneous whole-body ¹⁸F-FDG PET-MRI in primary staging of breast cancer: a pilot study.
    Taneja S; Jena A; Goel R; Sarin R; Kaul S
    Eur J Radiol; 2014 Dec; 83(12):2231-2239. PubMed ID: 25282709
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients.
    Poulsen MH; Bouchelouche K; Høilund-Carlsen PF; Petersen H; Gerke O; Steffansen SI; Marcussen N; Svolgaard N; Vach W; Geertsen U; Walter S
    BJU Int; 2012 Dec; 110(11):1666-71. PubMed ID: 22520686
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced nonsmall cell lung cancer--initial results.
    Plathow C; Aschoff P; Lichy MP; Eschmann S; Hehr T; Brink I; Claussen CD; Pfannenberg C; Schlemmer HP
    Invest Radiol; 2008 May; 43(5):290-7. PubMed ID: 18424949
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of whole-body PET/CT and PET/MRI in breast cancer patients: lesion detection and quantitation of 18F-deoxyglucose uptake in lesions and in normal organ tissues.
    Pace L; Nicolai E; Luongo A; Aiello M; Catalano OA; Soricelli A; Salvatore M
    Eur J Radiol; 2014 Feb; 83(2):289-96. PubMed ID: 24331845
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the Added Value of Diffusion-Weighted Imaging to Conventional Magnetic Resonance Imaging in Pancreatic Neuroendocrine Tumors and Comparison With 68Ga-DOTANOC Positron Emission Tomography/Computed Tomography.
    Farchione A; Rufini V; Brizi MG; Iacovazzo D; Larghi A; Massara RM; Petrone G; Poscia A; Treglia G; De Marinis L; Giordano A; Rindi G; Bonomo L
    Pancreas; 2016 Mar; 45(3):345-54. PubMed ID: 26418904
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A systematic review of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence.
    Pennant M; Takwoingi Y; Pennant L; Davenport C; Fry-Smith A; Eisinga A; Andronis L; Arvanitis T; Deeks J; Hyde C
    Health Technol Assess; 2010 Oct; 14(50):1-103. PubMed ID: 21044553
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of (18)F-FDG PET/CT in the diagnosis of breast cancer and lymph nodes metastases and micrometastases may be limited.
    Zhang X; Wu F; Han P
    Hell J Nucl Med; 2014; 17(3):177-83. PubMed ID: 25526754
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 179.